{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:58:04Z","timestamp":1789747084539,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010265","name":"Guizhou Medical University","doi-asserted-by":"publisher","award":["GMUSKL-202539"],"award-info":[{"award-number":["GMUSKL-202539"]}],"id":[{"id":"10.13039\/501100010265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560679"],"award-info":[{"award-number":["82560679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403718"],"award-info":[{"award-number":["82403718"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["CXPTXM[2025]010\/[2025]021\/KXJZ[2025]014"],"award-info":[{"award-number":["CXPTXM[2025]010\/[2025]021\/KXJZ[2025]014"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["YQK[2023]031"],"award-info":[{"award-number":["YQK[2023]031"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["zhongdian038"],"award-info":[{"award-number":["zhongdian038"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["KXJZ[2024]004"],"award-info":[{"award-number":["KXJZ[2024]004"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["ZSYS[2025]019"],"award-info":[{"award-number":["ZSYS[2025]019"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017957","name":"Health Commission of Guizhou Province","doi-asserted-by":"publisher","award":["gzwkj2026-046\/gzwkj2026-477"],"award-info":[{"award-number":["gzwkj2026-046\/gzwkj2026-477"]}],"id":[{"id":"10.13039\/100017957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109944","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:19:32Z","timestamp":1778084372000},"page":"109944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A novel FAK-targeted degrader: Design, synthesis, and therapeutic potential against colorectal cancer"],"prefix":"10.1016","volume":"178","author":[{"given":"Rong-Hong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Dong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Qian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Long","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Yi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109944_bb0005","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.7150\/thno.86547","article-title":"The spatial coexistence of TIGIT\/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Ma","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.109944_bb0010","article-title":"The current status of treatment for colorectal cancer in China: a systematic review","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.bioorg.2026.109944_bb0015","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1186\/s12885-020-07486-w","article-title":"Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China","volume":"20","author":"Peng","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.109944_bb0020","doi-asserted-by":"crossref","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: a review of current treatment and novel therapies","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J. Invest. Surg."},{"key":"10.1016\/j.bioorg.2026.109944_bb0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109944_bb0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1083\/jcb.200809110","article-title":"FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion","volume":"185","author":"Chan","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109944_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044041","article-title":"Cortactin as a target for FAK in the regulation of focal adhesion dynamics","volume":"7","author":"Tomar","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109944_bb0040","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.2174\/0929867328666210331143827","article-title":"Recent advances of small molecule focal adhesion kinase (FAK) inhibitors as promising anticancer therapeutics","volume":"28","author":"Lv","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0045","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/biom15091233","article-title":"Targeting focal adhesion kinase in lung diseases: current progress and future directions","volume":"15","author":"Wan","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.109944_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pharmthera.2013.12.003","article-title":"The role of FAK in tumor metabolism and therapy","volume":"142","author":"Zhang","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109944_bb0055","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/1061186X.2024.2385557","article-title":"Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, mechanistic insights and promising antitumor and safety profile","volume":"32","author":"Pecoraro","year":"2024","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bioorg.2026.109944_bb0060","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3389\/fimmu.2020.01624","article-title":"Colorectal cancer immunotherapy: options and strategies","volume":"11","author":"Johdi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.109944_bb0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","article-title":"Focal adhesion kinase: from biological functions to therapeutic strategies","volume":"12","author":"Tan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109944_bb0070","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109944_bb0075","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41467-020-15104-3","article-title":"Cancer associated fibroblast FAK regulates malignant cell metabolism","volume":"11","author":"Demircioglu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109944_bb0080","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/ijms23031726","article-title":"FAK in cancer: from mechanisms to therapeutic strategies","volume":"23","author":"Chuang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109944_bb0085","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4155\/fmc-2021-0015","article-title":"FAK inhibitors as promising anticancer targets: present and future directions","volume":"13","author":"Mustafa","year":"2021","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113573","article-title":"Design, synthesis, and biological evaluation of 2, 4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities","volume":"222","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0095","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2174\/1871520611313040003","article-title":"Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities","volume":"13","author":"Golubovskaya","year":"2013","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0100","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.2174\/0929867327666201103162239","article-title":"New insights on Fak and Fak inhibitors","volume":"28","author":"Brullo","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0105","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of Avutometinib \u00b1 Defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109944_bb0110","doi-asserted-by":"crossref","first-page":"14382","DOI":"10.1021\/acs.jmedchem.0c01248","article-title":"Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK)","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0115","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3390\/ijms21103630","article-title":"FAK family kinases in vascular diseases","volume":"21","author":"Murphy","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109944_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109944_bb0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/13543784.2020.1740680","article-title":"FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials","volume":"29","author":"Mohanty","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.109944_bb0130","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/acs.jmedchem.6b00487","article-title":"Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)","volume":"59","author":"Ott","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0135","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5246\/jcps.2024.09.057","article-title":"Cutting-edge FAK-targeting PROTACs: design, synthesis, and biological evaluation","volume":"33","author":"Wang","year":"2024","journal-title":"J. Chin. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109944_bb0140","doi-asserted-by":"crossref","first-page":"23515","DOI":"10.1002\/ange.202109237","article-title":"Discovery and characterisation of highly cooperative FAK-degrading PROTACs","volume":"133","author":"Law","year":"2021","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0145","article-title":"Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity","volume":"24","author":"Koide","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.bioorg.2026.109944_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The state of the art of PROTAC technologies for drug discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-biochem-032620-104421","article-title":"Driving E3 ligase substrate specificity for targeted protein degradation: lessons from nature and the laboratory","volume":"91","author":"Cowan","year":"2022","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0160","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1080\/14756366.2022.2100886","article-title":"Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs","volume":"37","author":"Qin","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0165","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/acsmedchemlett.9b00372","article-title":"Design, synthesis, and evaluation of highly potent FAK-targeting PROTACs","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109944_bb0170","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.bmcl.2017.02.072","article-title":"Synthesis of novel 1, 2, 4-triazine scaffold as FAK inhibitors with antitumor activity","volume":"27","author":"Dao","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109944_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112024","article-title":"Design, synthesis, biological evaluation and molecular docking study of novel thieno [3, 2-d] pyrimidine derivatives as potent FAK inhibitors","volume":"188","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114373","article-title":"Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: design, synthesis, and biological study","volume":"237","author":"Sun","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0185","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-mediated degradation of Bruton\u2019s tyrosine kinase is inhibited by covalent binding","volume":"14","author":"Tinworth","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109944_bb0190","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1021\/acs.jmedchem.1c00384","article-title":"Discovery of \u03b2-carboline derivatives as a highly potent cardioprotectant against myocardial ischemia-reperfusion injury","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113573","article-title":"Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities","volume":"222","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0200","article-title":"Nano proteolysis targeting chimeras (PROTACs) with anti-hook effect for tumor therapy","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2026.109944_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117585","article-title":"Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF\/VEGFR pathway","volume":"180","author":"Lorenc","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109944_bb0210","doi-asserted-by":"crossref","first-page":"18082","DOI":"10.1021\/acs.jmedchem.1c01496","article-title":"Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity","volume":"64","author":"Klein","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109944_bb0215","doi-asserted-by":"crossref","first-page":"8020","DOI":"10.3390\/molecules28248020","article-title":"The discovery of Indole-2-carboxylic acid derivatives as novel HIV-1 integrase strand transfer inhibitors","volume":"28","author":"Wang","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109944_bb0220","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1039\/D3RA08320A","article-title":"Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as novel HIV-1 integrase strand transfer inhibitors","volume":"14","author":"Zhang","year":"2024","journal-title":"RSC Adv."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:23:34Z","timestamp":1783171414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S0045206826004803"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109944","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel FAK-targeted degrader: Design, synthesis, and therapeutic potential against colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109944"}}